KLOW blend dosage: reported doses and schedule
GLOW plus KPV: a four-ingredient community blend with no human study of the combination found.
Also called: KLOW, KLOW blend, KLOW 80, KLOW stack, klow-blend.
Community blends · Unapproved community blend of GHK-Cu, BPC-157, TB-500 and KPV; contents and ratios vary.
Typical reported dose: 3.2 mg total once a day, 8 weeks on and 4 off
- Daily 80 mg vial report: 3.2 mg total per dose: GHK-Cu 2 mg + BPC-157 0.4 mg + reported thymosin ingredient 0.4 mg + KPV 0.4 mg. once daily, injection, depth not specified. Reported by users, rare report. Studied in: Adults describing self-use in a forum; identities, contents and outcomes unverified. (source)
- Five days on, two days off report: 4 mg total per dose: GHK-Cu 2.5 mg + BPC-157 0.5 mg + reported thymosin ingredient 0.5 mg + KPV 0.5 mg. once daily on five days each week, injection, depth not specified. Reported by users, rare report. Studied in: Adults describing self-use in a forum; identities, contents and outcomes unverified. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to KLOW blend
- Wolverine stack (BPC-157 + TB-500): An unapproved recovery blend with no controlled human trial of the premixed product.
- GLOW blend (GHK-Cu + BPC-157 + TB-500): An unapproved skin-and-recovery blend with no human combination study found.
Sources
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Evaluation of KPV-related Bulk Drug Substances (KPV (free base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List, FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), FDA · FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Allergies, NHS
- Eating, Diet, & Nutrition for Wilson Disease, NIDDK
- Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases., Froum S et al. · Frontiers in oral health · 2026
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain., Lee E et al. · Alternative therapies in health and medicine · 2021
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin., Miller TR et al. · Archives of facial plastic surgery · 2006
Sources checked: 2026-11-03.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.